TL;DR
This study implicates specific plasma proteins in FTD pathogenesis, with subtype-dependent effects, and identifies potential biomarkers for stratification and therapeutic targets.
Dementia is clinically and biologically heterogeneous, and genetically supported plasma protein associations across dementia subtypes remain incompletely characterized. We aimed to genetically prioritize plasma proteins associated with overall dementia and major dementia subtypes using proteome-wide Mendelian randomiza...
Despite the identification of numerous genetic risk variants for Alzheimer's disease (AD), mechanisms through which these variants act remain unclear. Identifying specific proteins levels affected by genetic variation can provide valuable insights into the underlying biological pathways implicated in AD. To gain more i...
The model’s accurate estimation of disease stages underscores the value of DEBM for patient stratification, offer a promising tool to support clinical trial design and provide a temporal ordering of multiple CSF proteins.
INTRODUCTION Pharmacological targets supported by genetic evidence demonstrate significantly higher success rates in clinical development. Osteoporosis (OP) represents a major global health burden; however, the causal plasma proteome underlying OP remains largely unexplored, limiting the discovery of effective circulat...
Blood metabolomics capture variation in biological aging, but the circulating proteins that underlie or accompany metabolomic aging and its links to disease and mortality remain underexplored. Here, we integrated metabolomics, proteomics and genetics from UK Biobank to characterize the protein architecture of metabolom...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
